4th Annual World Congress of MolMed-2014 (MolMed2014)

 ★ Welcome Message

Dear Friends and Colleagues,

I cordially welcome you to join the "BIT’s 4th Annual World Congress of MolMed-2014", which will be held during November 13-16, 2014 in Haikou, China. The aim of MolMed-2014 is to offer further high quality, broad spectrum program with the new Molecular Medicine technologies, beauty and intelligence realizations for better molecules delivered through case studies, lectures, posters and exhibitions on new strategies and methodologies.

Together with the Scientific Advisory Board Members, they undertook the difficult job of carefully evaluating the large number of submitted papers, considering the merits of each through detailed reviews and discussions, and selecting a technical program of the highest quality. The program of the coming MolMed-2014 conference promises to be very interesting for both basic scientists and executives who are working in the field of medicinal chemistry and other related areas, they will offer complete updates of recent developments and present the latest results in MolMed-2014.

On behalf of the Organizing Committee of MolMed-2014, I would firstly welcome all new participants and old friends again for your passionate involvements to these annual events. Secondly, I appreciate so much to all our scientific advisors, session organizers, supporters and hardworking organizing committee members for their enormous efforts to bring this grand program together.

We look forward to having you to be part of the must-attend event in  ★ Welcome Message

Dear Friends and Colleagues,

I cordially welcome you to join the "BIT’s 4th Annual World Congress of MolMed-2014", which will be held during November 13-16, 2014 in Haikou, China. The aim of MolMed-2014 is to offer further high quality, broad spectrum program with the new Molecular Medicine technologies, beauty and intelligence realizations for better molecules delivered through case studies, lectures, posters and exhibitions on new strategies and methodologies.

Together with the Scientific Advisory Board Members, they undertook the difficult job of carefully evaluating the large number of submitted papers, considering the merits of each through detailed reviews and discussions, and selecting a technical program of the highest quality. The program of the coming MolMed-2014 conference promises to be very interesting for both basic scientists and executives who are working in the field of medicinal chemistry and other related areas, they will offer complete updates of recent developments and present the latest results in MolMed-2014.

On behalf of the Organizing Committee of MolMed-2014, I would firstly welcome all new participants and old friends again for your passionate involvements to these annual events. Secondly, I appreciate so much to all our scientific advisors, session organizers, supporters and hardworking organizing committee members for their enormous efforts to bring this grand program together.

We look forward to having you to be part of the must-attend event in 2014.

★ Program Committee

Hosting Organizations

Information Research Center of International Talent, China
Haikou Municipal Government

Operating Organizations
Foreign Experts Databank of SAFEA-Dalian Experts Subdivision
BIT Congress, Inc., China
Haikou Convention and Exhibition Bureau
Hainan Harvest West Point M.I.C.E. Service Co.,Ltd

Executive Chair
Dr. Xiaodan Mei, President of BIT Congress Inc., China

Advisory Board Members

Dr. Amar Kamath, Vice President, BioReference Laboratories, USA
Dr. Axel M. Gressner, Professor, Clinical Chemist , Germany
Dr. Chen-Hsiung Yeh, Scientific Director, Quest Diagnostics Nichols Institute, USA
Dr. David Gelfand, CSO, WaferGen Bio-systems, Inc., USA
Dr. David Jackson, Senior Director, QIAGEN, Inc., UK
Dr. Dirk Zimmermann, Global Development Leader, Roche Diagnostics Ltd., Switzerland
Dr. Ellen Jo Baron, Professor, Stanford University, USA
Dr. Eric Fung, CSO, Vermillion Inc., USA
Dr. Francois Martelet, CEO, Topotarget A/S, Denmark
Dr. Frank Sharp, Professor, University of California at Davis, USA
Dr. Giorgio Secreto, Director, Italy's National Cancer Institute, Italy
Dr. Greg Maguire, CEO, BioRegenerative Sciences, USA
Dr. Heather Valentine, Vice President, Thermo Fisher Scientific, USA
Dr. Herb A. Fritsche, CSO, Health Discovery Corporation, USA
Dr. Herbert Budka, Head, Institute of Neurology, Medical University of Vienna, Austria
Dr. James Lipscomb, President, X-Bar Diagnostic Systems, Inc., USA
Dr. James L Zehnder, Professor, Stanford University School of Medicine, USA
Dr. Jan Groen, CEO. MDxHealth, Belgium
Dr. Mark Bradley, Professor, University of Edinburgh, UK
Dr. Phil Belgrader, Vice President, Akonnii Biosystems, Inc., USA
Dr. Qian Qi, Professor, Mayo Clinic, College of Medicine, USA
Dr. Stephen D. Barnhill, CEO, Health Discovery Corporation, USA
Dr. Steven H. Wong, Director, Wake Forest University School of Medicine, USA
Dr. Sven Beushausen, CSO, Aushon Biosystems, USA
Dr. Thomas Braun, CEO, Verisante Technology Inc., USA
Dr. Till T. Bachmann, Head, Division of Pathway Medicine, University of Edinburgh Medical School, UK
Dr. Willy Valdivia, CEO, Orion Integrated Biosciences, Inc., USA
Dr. Zhong Chen, CTO, China Medical Technologies, Inc., China
Dr. Alan S. Waggoner, Director, Carnegie Mellon University, USA
Dr. Anna Gukovskaya, Professor, University of California at Los Angeles, USA
Dr. Bruce Aronow, Scientific Director, University of Cincinnati College of Medicine, USA
Dr. Carl Taswell, President, Global TeleGenetics, Inc., USA
Dr. Charles Williams, Chair, ASF Scientific Advisory Committee, USA
Dr. Christoph M. Tang, Professor, Imperial College London, UK
Dr. Chuxia Deng, Chief, National Institutes of Health, USA
Dr. Craig Lehmann, Professor, Stony Brook University, USA
Dr. Damir Janigro, Professor, Cleveland Clinic Lerner College of Medicine, USA
Dr. David F. Jarrard, Professor, University of Wisconsin, USA
Dr. David P. Carbone, Professor, Vanderbilt University, USA
Dr. Dennis G McGonagle, Professor, University of Leeds, UK
Dr. Dinah Weissmann, Chairman, Biocortech, France
Dr. E. Schulze-Bahr, Professor, Hospital of the University of Munster, Germany
Dr. Eckhard von Keutz, Senior Vice President, Bayer Schering Pharma AG, Germany
Dr. Edward G. Garmey, Vice President, Arqule, Inc., USA
Dr. Fengtang Yang, Associate Editor, Wellcome Trust Sanger Institute, UK
Dr. Frederic Allemand, CBO, Biocortech, France
Dr. Fulton T. Crews, Professor, University of North Carolina at Chapel Hill, USA
Dr. Gideon Koren, Professor, Warren Alpert Medical School of Brown University, USA
Dr. Giulio Maria Pasinetti, Professor, Mount Sinai School of Medicine, USA
Dr. Gregory Lee, Professor, University of British Columbia, Canada
Dr. Helen H. Hobbs, Professor, Howard Hughes Medical Institute, USA
Dr. J. Yasha Kresh, Professor, Drexel University College of Medicine, USA
Dr. Jackie Hunter, Senior Vice President, GlaxoSmithKline, USA
Dr. Janet Woodcock, Director, US Food and Drug Administration, USA
Dr. Jason (Gang) Jin, CEO, ShanghaiBio Corporation, China
Dr. Jay Edelberg, Group Director, Bristol-Myers Squibb, USA
Dr. Jere P. Segrest, Professor, UAB Center for Computational and Structural Biology, USA
Dr. Johan Melendez, Director, Johns Hopkins University, USA
Dr. Johannes Streffer, Director, Johnson and Johnson Company, Belgium
Dr. John W. Erdman, Professor, University of Illinois, USA
Dr. Johnathan M. Lancaster, Director, Moffitt Cancer Center, USA
Dr. Jonathan O'Halloran, CSO, QuantuMDx Group Limited, UK
Dr. Josef Prchal, Professor of Medicine, University of Utah, USA
Dr. Julie R. Korenberg, Professor and Director, University of Utah, USA
Dr. Jun Wang, Executive Director, Beijing Genomics Institute at Shenzhen, China
Dr. Kenneth Becker, Professor, George Washington University, USA
Dr. Kohkan Shamsi, President, Berlex Laboratories Inc., USA
Dr. Krassen Dimitrov, Professor, University of Queensland, Australia

Dr. Said Rahnamaye Rabbani, Professor, University of São Paulo, Brazil

Conference Venue: Hainan International Convention & Exhibition Center

Hainan International Convention & Exhibition Center (HICEC) is one of HICEC CO., LTD projects and the main project of Hainan provincial and Haikou municipal government in 2009. It has developed as the important platform which provides service of convention, exhibition, hotel and combination of leisure, accommodation and commerce for modern service industry. As the main venue for 7th Pan-Pearl River Delta Regional Economic and Trade Fair, HICEC ended the Hainan’s convention and exhibition history of small scale and slow development. And it will develop as Hainan province’s high-level service platform for holding the international convention and business activities, and also the unique “City Name Card” for Haikou city in the future.

The HICEC’s main construction area is 136,200㎡with the investment of 1.38 billion RMB. HICEC’s Exhibition Center covers an area of 770,000㎡and the convention Center covers an area of 42,000㎡.TThe unique outlook style of HICEC has fully shown the tropical ocean element of Hainan. The style of roof is just like the wave, rolling rhythmically.